Inactivation of adenovirus types 5 and 6 by Virkon® S

Antiviral Research

Volumn 64, Issue 1, 2004, Pages 27-33

  McCormick, Lisa ^a   Maheshwari, Gargi ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adenovirus; Decontamination; Inactivation; Potency assay; Virkon S

Indexed keywords

DISINFECTANT AGENT; UNCLASSIFIED DRUG; VIRKON;

ADENOVIRUS 5; ARTICLE; BACTERIAL SPORE; BACTERIUM; CYTOTOXICITY; DILUTION; DISINFECTION; DRUG EFFICACY; FUNGUS; HUMAN; HUMAN CELL; LIQUID; PRIORITY JOURNAL; VIRUS ACTIVATION; VIRUS INFECTION; WASTE MANAGEMENT;

ADENOVIRUSES, HUMAN; ANTIVIRAL AGENTS; CELL LINE; DECONTAMINATION; DISINFECTANTS; HUMANS; PEROXIDES; SULFURIC ACIDS;

ADENOVIRIDAE; FUNGI;

EID: 4644305848     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2004.04.008     Document Type: Article

References (17)

1. Angelillo I.F., Bianco A., Nobile C.G.A., Pavia M. Evaluation of the efficacy of glutaraldehyde and peroxygen for disinfection of dental instruments. Lett. Appl. Microbiol. 27:1998;292-296
2. Doblhoff-Dier O., Bliem R. Quality control and assurance from the development to the production of biopharmaceuticals. Trends Biotechnol. 17:1999;266-270
3. Gasparini R., Pozzi T., Magnelli R., Fatighenti D., Giotti E., Poliseno G., Pratelli M., Severini R., Bonanni P., Feo L.D. Evaluation of in vitro efficacy of the disinfectant Virkon. Eur. J. Epidemiol. 11:1995;193-197
4. Gould E.A. Methods for long-term virus preservation. Mol. Biotechnol. 13:1999;57-66
5. Hernandez A., Martro E., Matas L., Martin M., Ausina V.. Assessment of in-vitro efficacy of 1% Virkon against bacteria, fungi, viruses and spores by means of AFNOR guidelines. J. Hosp. Infect. 46:2000;203-209
6. Larzul D. Viral validation design of a manufacturing process. Dev. Biol. Stand. 99:1999;139-150
7. Limbach K.J., Paoletti E. Non-replicating expression vectors: applications in vaccine development and gene therapy. Epidemiol. Infect. 116(3):1996;241-256
8. Luff P.R. Control of manufacture - principles and purposes. Dev. Biol. Stand. 79:1992;155-158
9. Maheshwari G., Jannat R., McCormick L., Hsu D. Thermal inactivation of adenovirus type 5. J. Virol. Methods. 118:2004;141-145
10. Michelson, S., Schofield, T., 1996. The Biostatistics Cookbook: The Most User-Friendly Guide for the Bio/Medical Scientist. Kluwer Academic Publishers, Boston.
11. Nadeau I., Kamen A. Production of adenovirus vector for gene therapy. Biotechnol. Adv. 20(7-8):2003;475-489
12. Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55:2004;355-372
13. Sofer G. Validation of biotechnology products and processes. Curr. Opin. Biotechnol. 6:1995;230-234
14. Sofer G. Virus Inactivation in the 1990s and into the 21st Century. Part 5: disinfection. Biopharmaceuticals. 16(2):2003;44-48
15. Spickett C.M., Jerlich A., Panasenko O.M., Arnhold J., Pitt A.R., Stelmaszynska T., Schaur R.J. The reactions of hypochlorous acid, the reactive oxygen species produced by myeloperoxidase, with lipids. Acta Biochim. Pol. 47(4):2000;889-899
16. White, E.M., Grun, J.B., Sun, C.S., Sito, A.F., 1991. Process validation for virus removal and inactivation. Biopharmaceuticals 4(5), 34-39, www.antecint.co.uk.
17. Zhang W.-W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene. Ther. 6(2):1999;113-138